RxDoctor Payments Data

Connor Brass

Ophthalmology · Kansas City, KSNPI 1952837882

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Alcon at 35.9% of the total.

$1,823in general payments, 2019–2025

Across 71 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$654
  • Bausch & Lomb Americas Inc.$276
  • Sun Pharmaceutical Industries Inc.$245
  • Glaukos Corporation$152
  • Oyster Point Pharma, Inc.$100
  • Sight Sciences, Inc.$78
  • plus $318 from 7 others

What the payments were for

  • Food & beverage$1,823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,823 in reported general payments places this provider in the 55th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$484,649
Medicare patients
1,318
Services billed
3,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost45$25,445
RestasisCyclosporine19$21,760
Latanoprost519$6,152
SimbrinzaBrinzolamide/Brimonidine Tart17$3,475
Prednisolone Acetate88$2,619
Timolol Maleate214$2,077
Brimonidine Tartrate152$1,255
Dorzolamide Hcl50$1,228
ValacyclovirValacyclovir Hcl23$1,178
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha46$538
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$530
MoxifloxacinMoxifloxacin Hcl29$481
Doxycycline Hyclate19$391
Doxycycline Monohydrate26$297
ErythromycinErythromycin Base22$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$47$47,20564 claims
AlconSimbrinza$654$3,47517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →